What Sequentia Biotech does

Sequentia Biotech S.L. is a Barcelona-based bioinformatics company founded in 2013 that builds proprietary software platforms and provides consulting services to translate multiomics data — genomics, transcriptomics, metagenomics, epigenomics, proteomics, and metabolomics — into actionable biological and clinical insights. Its product portfolio spans AI-powered SaaS tools (AIR for RNA-Seq expression analysis, GAIA for metagenomics with benchmarked long-read performance), regulated clinical diagnostics (MICK Clinical, CE-IVD marked for gastrointestinal pathogen detection; MICK-MAGMA for tuberculosis genomics), research platforms (MICK for microbiome dysbiosis, GINO for human genomics, PROKY for outbreak surveillance, SABIO for genome safety), and workflow infrastructure (Sequentia Hub integration ecosystem and BatchX no-code job management). The company holds ISO 13485:2016, CE-IVD, GDPR, and HIPAA certifications, supporting both research-use and clinical diagnostic deployments, and has completed 900+ bioinformatics projects with 80+ peer-reviewed publications.

The company runs a hybrid go-to-market: product-led growth for AIR and GAIA via free trial and subscription (Stripe/PayPal/Braintree), and direct enterprise field sales for pharma, biotech, clinical labs, agricultural firms, and academic customers. Revenue streams include SaaS subscriptions, bioinformatics consulting, custom software development, sequencing services (including Oxford Nanopore long-read integration), training programs, and one-time CE-IVD product licenses. Customers span six primary verticals — Academic & Public Research Institutions, Pharma & Biotech, Clinical Diagnostic Labs, Agriculture & Agritech, Food & Nutrition Industry, and NGS Industry Partners — across 65+ countries, though no enterprise customer names are publicly disclosed. Notable technical collaborations include a Smart Bridge orchestration layer for Oxford Nanopore long-read sequencing in a European clinical diagnostics laboratory and AWS-hosted cloud delivery for SaaS and BatchX platforms.

Sequentia secured a €10 million Series A in October 2024 led by Seventure Partners (€7M) with co-investment from the European Innovation Council Fund (€3M), following earlier funding of approximately €2.5M from the EIC (October 2021) and a smaller EISMEA grant in 2017. The Series A is earmarked for commercialization and expansion of the MICK microbiome platform across biomedicine, precision medicine, agriculture, and food industries. Leadership: Walter Sanseverino serves as CEO and co-founder.

Name

Sequentia Biotech

Legal name

Sequentia Biotech S.L.

Website

https://sequentiabiotech.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

Barcelona-based bioinformatics company (founded 2013) that builds proprietary multiomics software platforms (MICK, GAIA, AIR, GINO) and provides consulting, sequencing, and CE-IVD clinical diagnostic services to pharma, biotech, clinical labs, agriculture, and academic customers across 65+ countries.

Ownership category

akta.pro rank

Product category

Bioinformatics Software

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Software Publishers (5132), Custom Computer Programming Services (541511), Other Scientific and Technical Consulting Services (54169)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Prepackaged Software (7372)

akta.pro primary industry

Microbiome Analytics, Sequencing & Bioinformatics Platforms (HLAAAFAI)

akta.pro secondary industries

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Transcriptomics & Gene Expression Profiling Services (HLAGANAE), Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD)

Keywords

• Bioinformatics software
• Multi-omics analysis
• Genomic data analytics
• Metagenomics software
• Clinical diagnostic bioinformatics

Headquarters

HQ city

Barcelona

HQ country

Spain

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations

Revenue model

1. SaaS Software Subscriptions (AIR, GAIA): Cloud-based software-as-a-service products for RNA-Seq analysis (AIR) and metagenomics (GAIA). Available via subscription with free trial access. Users register and subscribe through the website, with payment processed via Stripe, PayPal, and Braintree.
2. Bioinformatics Consulting Services: End-to-end bioinformatics consulting supporting multiomics projects across experimental design, data analysis, and interpretation. Offered as a professional service to academic and industry clients.
3. Custom Software Development: Development of bespoke bioinformatics pipelines, data visualization dashboards, and tailored analysis platforms for specific client research needs, delivered as project-based professional services.
4. Sequencing Services: High-quality next-generation sequencing (NGS) data generation, including long-read Oxford Nanopore sequencing, seamlessly integrated with downstream bioinformatics analysis for end-to-end sample-to-insight services.
5. Training Services: Hands-on bioinformatics training workshops and customized courses for teams, covering omics data analysis and interpretation. Offered as instructor-led or blended learning formats.
6. Licensed Diagnostic Products (CE-IVD): CE-IVD certified clinical diagnostic products (MICK Clinical) licensed for use in clinical diagnostic laboratories in Europe. Represents a product license revenue stream beyond pure software SaaS.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels9 records

Core offering

Sequentia Biotech develops and sells proprietary bioinformatics software platforms (MICK, GAIA, AIR, GINO, PROKY, SABIO, BatchX, Sequentia Hub) that transform multiomics sequencing data into actionable biological and clinical insights. The company delivers these platforms alongside end-to-end bioinformatics consulting, custom software development, sequencing services, and training programs to pharma, biotech, clinical diagnostic labs, academic institutions, agriculture, and food industry clients across 65+ countries.

Product overview

Sequentia Biotech offers a platform-plus-modules architecture centered on bioinformatics solutions for omics data analysis. The core commercial SaaS products are AIR (AI-powered RNA-Seq expression analysis) and GAIA (universal metagenomics software), sold as subscription services. The MICK product line provides microbiome analysis capabilities, including MICK Clinical (CE-IVD marked clinical diagnostic for GI pathogen detection), MICK-MAGMA (TB genomics), and the base MICK platform for microbiome dysbiosis insights. Supporting products include GINO (human genomics), PROKY (outbreak detection), and SABIO (genome safety). The ecosystem is unified through Sequentia Hub (integration platform) and BatchX (no-code job management). The company also provides associated services including bioinformatics consulting, custom software development, sequencing services, and training programs.

Differentiator

Problem solved

Functional benefit

Brands

• MICK: Microbiome Dysbiosis Insights platform for microbiome analysis
• GAIA
• GINO
• AIR
• PROKY
• SABIO
• BatchX
• Sequentia Hub

Products and services

• MICK (Microbiome Dysbiosis Insights) Proprietary microbiome analysis platform providing species-level profiling and dysbiosis assessments for human health diagnostics and research applications, available to pharma, biotech, clinical labs, academic, and food industry clients.
• MICK Clinical (CE-IVD) CE-IVD certified clinical diagnostic product for automated gastrointestinal pathogen detection and identification from patient samples, licensed for clinical use in European diagnostic laboratories.
• MICK-MAGMA (TB Genomics & Treatment) Genomic and resistance profiling solution for tuberculosis providing treatment insights to support clinical decision-making for TB patients.
• GAIA (Metagenomics Insights) Universal metagenomic analysis software for taxonomic classification of microorganisms from diverse sequencing datasets, supporting both short-read and long-read technologies. Offered as a SaaS product with free trial access.
• GAIA Clinical (RUO) Clinical metagenomics solution (Research Use Only) enabling comprehensive microbial profiling from clinical samples for research applications in clinical laboratories.
• GINO (Human Genomics) Proprietary human genomics platform for analyzing human genetic variation and gene expression patterns to support genomic research and clinical interpretation.
• AIR (RNA-Seq Expression Analysis) AI-powered RNA-Seq expression analysis software for gene expression profiling, differential expression analysis, and biomarker discovery, offered as a SaaS subscription with free trial access.
• PROKY (Outbreak Detection & Analysis) Outbreak detection and surveillance platform for epidemiology and public health applications, enabling identification and analysis of disease outbreak patterns.
• SABIO (Genome Safety Software) Genome safety software for food and industrial applications, ensuring genomic analysis quality and biosafety compliance for production organisms.
• Sequentia Hub Connected cloud-based ecosystem platform integrating all Sequentia bioinformatics solutions, enabling centralized data management, workflow automation, and cross-platform analysis.
• BatchX No-code cloud platform enabling users to manage and execute bioinformatics jobs without programming expertise, providing accessible workflow control for bioinformatics teams.
• Bioinformatics Consulting End-to-end bioinformatics consulting supporting multiomics projects across experimental design, data analysis, and interpretation for academic and industry clients.
• Custom Software Development Custom bioinformatics pipeline, data visualization dashboard, and analysis platform development tailored to specific research or operational requirements, delivered as project-based engagements.
• Sequencing Services High-quality next-generation sequencing (NGS) data generation including long-read Oxford Nanopore sequencing, seamlessly integrated with downstream bioinformatics analysis for end-to-end sample-to-insight workflows.
• Training Hands-on bioinformatics workshops and customized courses equipping teams with skills and knowledge to independently manage and interpret omics data, offered as instructor-led or blended learning formats.

Quantifiable outcome

• Over 900 bioinformatics projects completed
• +3 more outcomes

Named customers10 records

Segments6 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature10 records

Partnerships

Two partnerships are on record, tiered core.

• Oxford Nanopore TechnologiescoreTechnology or IntegrationSequentia Biotech partnered with a large European clinical diagnostics laboratory to implement its Smart Bridge orchestration layer for Oxford Nanopore (ONT) long-read sequencing. The specialized bridge converts raw ONT sequencing output into standardized, clinician-ready reports, creating an automated 'pore to PDF' ecosystem integrated with ONT's sequencing platform.
• AWS (Amazon Web Services)coreTechnology or IntegrationSequentia Biotech's cloud-based platforms (BatchX, Sequentia Hub, and SaaS products AIR and GAIA) are hosted on cloud infrastructure, with AWS referenced as the hosting provider. The company leverages cloud computing for scalable bioinformatics analysis, data storage, and platform delivery.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• QIAGEN: Global life sciences leader providing sample-prep and bioinformatics tools (CLC Genomics Workbench, GeneGlobe) for genomics and clinical diagnostics. Comparable to Sequentia in serving pharma/biotech and clinical labs with integrated bioinformatics, but at vastly larger scale and as part of a broader consumables portfolio.
• Illumina: Dominant sequencing platform vendor increasingly bundling bioinformatics (DRAGEN, BaseSpace). Comparable as an end-to-end provider for genomics customers, though Illumina's primary moat is sequencing hardware rather than software interpretation.
• Dotmatics: Scientific R&D informatics platform serving pharma/biotech customers with data management and analysis workflows. Comparable to Sequentia in targeting pharma R&D with integrated data/analysis offerings, though Dotmatics spans broader chemistry and biology informatics.
• Genedata: Enterprise bioinformatics platform for pharma/biotech R&D with specialized omics and screening analysis modules. Comparable to Sequentia Hub as an enterprise-scale platform for multiomics interpretation in pharma R&D contexts.

Direct peers

• SOPHiA GENETICS: Clinical genomics AI platform serving hospitals and clinical labs with multiomics interpretation, including metagenomics and rare disease applications. Closely comparable to Sequentia in combining clinical-grade certification, AI-driven interpretation, and SaaS deployment for clinical diagnostics customers.
• DNAnexus: Cloud-based genomics informatics platform serving pharma/biotech and clinical customers with analysis pipelines and data management. Comparable to Sequentia Hub as a cloud bioinformatics ecosystem, though DNAnexus focuses more on infrastructure and large pharma deployments.
• Benchling: Cloud platform for biotech R&D including molecular biology and genomics workflows, serving pharma/biotech enterprise customers. Comparable to Sequentia as a SaaS bioinformatics platform for life science R&D, though Benchling's emphasis is broader R&D informatics rather than omics interpretation.
• Partek: Bioinformatics software provider specializing in genomics and transcriptomics analysis (Partek Flow, Partek Genomics Suite). Comparable to Sequentia's AIR and GINO products for academic and pharma customers seeking user-friendly omics analysis.
• Qlucore: Visualization and analysis software for omics data including genomics, transcriptomics, and proteomics, serving clinical and research customers. Comparable to Sequentia's AIR/GAIA as a specialized omics interpretation tool with CE-marked clinical variants.
• Eagle Genomics: Bioinformatics platform applying AI to microbiome and multiomics analysis for enterprise customers in consumer goods, food, and life sciences. Closely comparable to Sequentia's microbiome focus and cross-vertical positioning in food/agriculture/health.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/SequentiaBio
• LinkedInlinkedin.com/company/sequentiabiotech

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds4 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sequentia Biotech